Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 50INDUSTRY 17NIH 4NETWORK 3UNKNOWN 1OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 7Breast Neoplasms 6Stomach Neoplasms 4Uterine Cervical Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thymoma 1Small Cell Lung Carcinoma 1Recurrence 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Fibrosis Of Extraocular Muscles, Congenital, 3A, with or without Extraocular Involvement 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1EGFR Positive Non-small Cell Lung Cancer 1Carcinoma, Ovarian Epithelial 1Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction 1

Interventions

Cisplatin 3sintilimab 2toripalimab 1camrelizumab 1anlotinib 1TP protocol 1Radiotherapy 1Radiation 1Paclitaxel 1Nivolumab 1Neoadjuvant Therapy 1Immune Checkpoint Inhibitors 1Fluorouracil 1Docetaxel 1Chemoradiotherapy 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Esophageal Squamous Cell Carcinoma × Paclitaxel × Clear all
NCT04063683 2021-08-24

Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC).

Henan Cancer Hospital

Phase 2 Unknown
47 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡